Characterization of bacterial and viral pathogens in the respiratory tract of children with HIV-associated chronic lung disease: a case‒control study

Prince K. Mushunje; Felix S. Dube; Jon Ø Odland; Rashida A Ferrand; Mark P. Nicol; Regina E. Abotsi; The BREATHE study team

doi:10.1101/2023.09.11.23295188

ABSTRACT

Introduction Chronic lung disease is a major cause of morbidity in African children with HIV infection; however, the microbial determinants of HIV-associated chronic lung disease (HCLD) remain poorly understood. We conducted a case-control study to investigate the prevalence and densities of respiratory microbes among pneumococcal conjugate vaccine (PCV)-naïve children with (HCLD+) and without HCLD (HCLD-) established on antiretroviral treatment (ART).

Methods Nasopharyngeal swabs collected from HCLD+ (defined as forced-expiratory-volume/second<-1.0 without reversibility postbronchodilation) and age-, site-, sex- and duration-of-ART-matched HCLD-enrolled in Zimbabwe and Malawi (BREATHE trial-NCT02426112) were tested for seven bacteria, including Streptococcus pneumoniae (SP), Staphylococcus aureus (SA), Haemophilus influenzae (HI), Moraxella catarrhalis (MC), and five viruses, including human rhinovirus (HRV), respiratory syncytial virus A or B, and human metapneumovirus, using qPCR (Fluidigm). Fisher’s exact test and logistic regression analysis were used for between-group comparisons and risk factors associated with common respiratory microbes, respectively.

Results A total of 345 participants (287 HCLD+, 58 HCLD-; median age, 15.5 years [IQR=12.8–18], females, 52%) were included in the final analysis. SP (40%[116/287] vs. 21%[12/58], p = 0.005) and HRV (7%[21/287] vs. 0%[0/58], p = 0.032) were more prevalent in HCLD+ patients than in HCLD-patients. Viruses (predominantly HRV) were detected only in HCLD+ participants. HI (1.55×10⁴ CFU/ml vs. 2.55×10² CFU/ml, p = 0.006) and MC (1.14×10⁴ CFU/ml vs. 1.45×10³ CFU/ml, p = 0.031) densities were higher in HCLD+. Bacterial codetection (≥ any 2 bacteria) was higher in the HCLD+ group (36% [114/287] vs. (19% [11/58]), (p = 0.014), with SP and HI codetection (HCLD+: 30% [86/287] vs. HCLD-: 12% [7/58], p = 0.005) being the most frequent. In 128 SP-positive participants (116 HCLD+, 12 HCLD-), 66% [85/128] of participants had non-PCV-13 serotypes detected. Serotypes 13 and 21 (9% [8/85] each) and PCV-13 serotypes (4, 19A, 19F: 16% [7/43] each) were more prevalent. Study participants with a history of previous tuberculosis treatment were more likely to carry SP or HI, while those who used ART for ≥2 years were less likely to carry HI and MC.

Conclusion Children with HCLD+ were more likely to be colonized by SP and HRV and had higher HI and MC bacterial loads in their nasopharynx. The role of SP, HI, and HRV in the pathogenesis of CLD, including how they influence the risk of acute exacerbations, should be studied further.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT02426112

Funding Statement

This parent study was funded by the Global Health and Vaccination Research (GLOBVAC) Programme of the Medical Research Council of Norway. This substudy was funded by the Royal Society through the Future Leaders African Independent Research award and the National Institute for Health Research (NIHR) Global Health Research Unit on Mucosal Pathogens using UK aid from the UK Government (Project number 16/136/46). The views expressed are those of the authors and not necessarily those of the NIHR, the Department of Health and Social Care. PM received funding from the UCT Postgraduate Funding, UCT's Building Research Active Academic Staff (B.R.A.A.S.) award, the Molecular and Cell Biology Equity Development Programme scholarship, and the Dube-lab scholarship. REA acknowledges the financial support of the Swedish International Development Cooperation Agency (SIDA) through the Organization of Women in Science for the developing world (OWSD) PhD Fellowship, Margaret McNamara Education Grants and L'Oreal UNESCO For Women in Science PhD Fellowship. MN is supported by an Australian National Health and Medical Research Council Investigator Grant [APP1174455]. FSD is supported by the National Research Foundation of South Africa (112160), Future Leaders-African Independent Research (FLAIR) Fellowship, the National Institute for Health Research (NIHR) Global Health Research Unit on Mucosal Pathogens using UK aid from the UK Government, the University of Cape Town and the Allergy Society of South Africa (ALLSA). RAF is funded by the Wellcome Trust (206316Z17Z). The funders had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The parent study (BREATHE) was approved by the Human Research and Ethics Committee of the University of Cape Town(HREC/REF:754/2015), the London School of Hygiene and Tropical Medicine Ethics Committee (reference 8818), the Harare Central Hospital Ethics Committee and Medical Research Council of Zimbabwe (reference MRCZ/A/1946), the College of Medicine Research Ethics Committee Malawi (reference P.04/15/1719) and the Regional Committee for Medical and Health Research Ethics, Northern Norway (reference 2015/1650). The University of Oxford waived approval. Additional ethical approval was received for this substudy from the UCT HREC (HREC/REF: 092/2019). No additional data were collected other than those approved in the parent study.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Availability of data and materials

The datasets used and analyzed during the current study are available from Felix Dube (sizwe.dube{at}uct.ac.za) on reasonable request and ethical approval.